氟比洛芬CAS: 51543-40-9;5104-49-4原料供应发货南京工厂直销

中文名氟比洛芬
英文名(2r)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid
别名氟比洛芬
r-氟比洛
(r)-氟比洛芬
r(-)氟比洛芬
(r)-2-氟比洛芬
氟比洛芬 ep标准品
(r)-(-)-2-氟-Α-甲基-4-联苯乙酸
(r)-(-)-2-氟-alpha-甲基-4-联苯乙酸
(r)-(-)-2-氟-alpha-甲基-4-联苯乙酸
英文别名flurizan
mpc7869
flurbiprofen
(r)-2-flurbiprofen
(2r)-2-(2-fluorobiphenyl-4-yl)propanoic acid
(2r)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid
(r)-2-fluoro-α-methyl-1,1'-biphenyl-4-acetic acid
(r)-α-methyl-2-fluoro-1,1'-biphenyl-4-acetic acid
(r)-(-)-2-fluoro-alpha-methyl-4-biphenylacetic acid
1,4-bis(1,1,1,2,3,3,3-heptafluoropropan-2-yl)benzene
[1,1'-biphenyl]-4-aceticacid, 2-fluoro-a-methyl-,(ar)-
(r)-(-)-2-fluoro-alpha-methyl-4-biphenylacetic acid(flurbiprofe
[1,1'-biphenyl]-4-acetic acid, 2-fluoro-alpha-methyl-,(alphar)-
cas51543-40-9
5104-49-4
einecs257-264-7化学式c15h13fo2
分子量244.26inchiinchi=1/c12h4f14/c13-7(9(15,16)17,10(18,19)20)5-1-2-6(4-3-5)8(14,11(21,22)23)12(24,25)26/h1-4h密度1.199±0.06 g/cm3(predicted)熔点110-113°c(lit.)沸点376.2±30.0 °c(predicted)闪点57.7°c蒸汽压2.84mmhg at 25°c溶解度soluble  in  dmso  (50  mg/ml),  methanol  (50  mg/ml),  ethanol  (~100  mg/ml),  dmf  (~100  mg/ml)折射率1.34酸度系数4.14±0.10(predicted)存储条件room temprature外观crystalline powder颜色white to off-whitemdl号mfcd00079303体外研究tarenflurbil ((r)-flurbiprofen) can significantly reduce aβsecretion, but at the same time, increases the level ofintracellular aβ. the binding between [ 3 h]9-cis-ra and rxrα iscompetitively inhibited by both unlabeled (r)-flurbiprofen and9-cis-ra. (r)-flurbiprofen can interfere with the interactionbetween rxrα and 9-cis-retinoid acid (9-cis-ra), and that 9-cis-radecreases tarenflurbil ((r)-flurbiprofen)’s reduction of aβsecretion. tarenflurbil ((r)-flurbiprofen) treatment significantlyincreases the levels of intracellular aβ species. the wellcharacterized, nonsteroidal anti-inflammatory drug (nonsteroidalanti-inflammatory drug), tarenflurbil ((r)-flurbiprofen) affectsonly aβ and not notch β formation, indicating that secondgeneration gsms and nonsteroidal anti-inflammatory drug-based gsmshave different modes of action regarding notch processing.体内研究effects of the early and late onset of treatment with tarenflurbil((r)-flurbiprofen) are assessed in c57bl6/j mice that develop anon-remitting form of the disease, and in sjl mice that develop arelapsing-remitting (rr)-eae. tarenflurbil ((r)-flurbiprofen)completely prevents the development of clinical eae scores inc57bl6/j mice when the treatment is started within 3 days afterimmunization. this regimen is referred to as preventive treatment.the effect is dose-dependent, and the minimum daily dose forcomplete prevention is 5 mg/kg/day. effects of tarenflurbil((r)-flurbiprofen) are comparable to those of fingolimod (fty720,0.5 mg/kg/day), which is used as the positive control. tarenflurbil((r)-flurbiprofen) also significantly reduces clinical eae scoresin c57bl6/j mice when treatment is started shortly before onset ofclinical manifestations, referred to as semi-therapeutic (10mg/kg/day) and reduces clinical scores when the treatment isinitiated after full development of the disease on day 13 (5mg/g/day).